Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1822-1826

  Okusanya, Olanrewaju ^a   Forrest, Alan ^a   DiFrancesco, Robin ^a   Bilic, Sanela ^a   Rosenkranz, Susan ^b   Para, Michael F ^c   Adams, Elizabeth ^d   Yarasheski, Kevin E ^e   Reichman, Richard C ^f   Morse, Gene D ^a   Brizz, Barbara ^g   Segal, Yoninah ^h   Walawander, Ann ⁱ   Ashton, Courtney ⁱ   Ferguson, Elaine ^j   De Caprariis, Pascal J ^k   Saah, Alfred J ^k   Becker, Mark ^k   Wire, Mary ^l   Shelton, Mark ^l  

^a UNIVERSITY AT BUFFALO   (United States)

^b HARVARD UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g ACTG Operations Center   (United States)

^h Statistical Data Analysis Center   (United States)

ⁱ Data Management Center   (United States)

^j Division of AIDS

^k Division of AIDS ^*  (United States)

^l GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-HIV AGENTS; CARBAMATES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SULFONAMIDES;

EID: 34248379038     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00570-06     Document Type: Article

References (24)

1. Akaike, H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
2. Cremers, S., R. Schoemaker, E. Scholten, J. den Hartigh, J. Konig-Quartel, E. van Kan, L. Paul, and J. de Fijter. 2005. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modeling. Br. J. Clin. Pharmacol. 60:249-256.
3. D'Argenio, D., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic system analysis software. Biomedical Simulations Resource, Los Angeles, CA.
4. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
5. Frerichs, V. A., R. DiFrancesco, and G. D. Morse. 2003. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 787:393-403.
6. Furfine, E. S., C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein. 2004. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48:791-798.
7. Goujard, C., I. Vincent, J. L. Meynard, N. Choudet, D. Bollens, C. Rousseau, D. Demarles, C. Gillotin, R. Bidault, and A. M. Taburet. 2003. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 47:118-123.
8. Jeong, E. J., X. Liu, X. Jia, J. Chen, and M. Hu. 2005. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab. 6:455-468.
9. Jusko, W. J. 1992. Guidelines for collection and analysis of pharmacokinetic data, p. 21-43. In W. E. Evans, W. J. Jusko, and J. J. Schentag (ed.), Applied pharmacokinetics, 3rd ed. Applied Therapeutics, Washington, DC.
10. Keil, K., V. A. Frerichs, R. DiFrancesco, and G. D. Morse. 2003. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma. Ther. Drug Monit. 25:340-346.
11. Kuchimanchi, K. R., C. Udata, T. P. Johnston, and A. K. Mitra. 2000. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats. Drug Metab. Dispos. 28:403-408.
12. Liu, Y., Y. Liu, Y. Dai, L. Xun, and M. Hu. 2003. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J. Altern. Complement. Med. 9:631-640.
13. Roberts, M. S., B. M. Magnusson, F. J. Burczynski, and M. Weiss. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-790.
14. Sadler, B. M., C. Gillotin, Y. Lou, J. J. Eron, W. Lang, R. Haubrich, and D. S. Stein. 2001. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob. Agents Chemother. 45:3663-3668.
15. Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
16. Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. 43:1686-1692.
17. Shelton, M. J., S. L. Ford, J. Borland, Y. Lou, M. B. Wire, S. S. Min, Z. G. Xue, and G. Yuen. 2006. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J. Acquir. Immune Defic. Syndr. 42:61-67.
18. Shelton, M. J., M. B. Wire, Y. Lou, B. Adamkiewicz, and S. S. Min. 2006. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob. Agents Chemother. 50:928-934.
19. Shou, M., W. Lu, P. H. Kari, C. Xiang, Y. Liang, P. Lu, D. Cui, W. B. Emary, K. B. Michel, J. K. Adelsberger, J. E. Brunner, and A. D. Rodrigues. 2005. Population pharmacokinetic modeling for enterohepatic recirculation in rhesus monkey. Eur. J. Pharm. Sci. 26:151-161.
20. Steimer, J. L., A. Mallet, J. L. Golmard, and J. F. Boisvieux. 1984. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab. Rev. 15:265-292.
21. Veronese, L., J. Rautaureau, B. M. Sadler, C. Gillotin, J.-P. Petite, B. Pillegand, M. Delvaux, C. Masliah, S. Fosse, Y. Lou, and D. S. Stein. 2000. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob. Agents Chemother. 44:821-826.
22. Wang, Y., A. Roy, L. Sun, and C. E. Lau. 1999. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab. Dispos. 27:855-859.
23. Wire, M. B., K. L. Baker, L. S. Jones, M. J. Shelton, Y. Lou, G. J. Thomas, and M. M. Berrey. 2006. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob. Agents Chemother. 50:1578-1580.
24. Wire, M. B., M. J. Shelton, and S. Studenberg. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45:137-168.